Topic regenerative medicine

Products regenerative medicine

Sample Preparation Products for Epigenetics & Regenerative Medicine

Visitors to Achema Stand F44 in Halle 4.2 will be able to see Porvair Sciences' growing range of tissue culture plastics which, while affordably priced, are made to the highest more

News regenerative medicine

• Cellzome awarded UK’s Technology Strategy Board grant as part of the Regenerative Medicine Programme

  Cellzome announced the award of a grant by the UK government-backed Technology Strategy Board under its Regenerative Medicine Programme: “Tools and Technologies” for a project which will address the need for better  characterisation of human stem cells.  Cellzome will use its EpisphereTM technology more

• Karolinska Institutet and Mayo Clinic strengthen their cooperation

  The scope of Karolinska Institutet’s cooperation with Mayo Clinic is now being extended through a formal contract. A delegation from Mayo Clinic is coming to Stockholm, and the cooperation is being marked by a major international conference.”Mayo Clinic has succeeded in combining world-leading resea more

• Research group headed by Professor Takashi Tsuji demonstrates in regenerating “fully functional bioengineered mature tooth unit”

  Donor organ transplantation is currently an essential therapeutic approach to the replacement of a dysfunctional organ as a result of disease, injury or aging in vivo. Recent progress in the area of regenerative therapy has the potential to lead to bioengineered mature organ replacement in the futur more

Job offers regenerative medicine

• Inside Sales Representatives (f/m)
  

  STEMCELL Technologies Inc is a privately-owned biotechnology company that helps power leading-edge life sciences research around the world. Scientists performing stem cell, immunology, cancer, regenerative medicine and cellular therapy research are among those who rely on our cell culture media, cel more

Publications regenerative medicine

• Intermediate‐conductance Ca2+‐activated potassium and volume‐sensitive chloride channels in endothelial progenitor cells from rat bone marrow mononuclear cells

  Abstract Aim Bone marrow endothelial progenitor cells (BMEPCs) are believed to be a promising cell source for regenerative medicine; however, their electrophysiology properties have not been fully clarified, which is important to the clinical application of BMEPCs. The current study was designe more

• Secreted factors from adipose tissue increase adipogenic differentiation of mesenchymal stem cells

  Abstract Objectives Adipose tissue engineering is one of the hottest topics in the field of regenerative medicine. Fat tissue has been considered as an abundant and accessible source of adult stem cells by tissue engineers, since it gives rise to adipose stem cells. However, recent reports have more

• Proteomic analysis of the impact of static culturing on the expansion of rat bone marrow mesenchymal stem cells

  The clinical potential of mesenchymal stem cells (MSC) in tissue engineering and regenerative medicine is due to their self-renewal, proliferation and multi-lineage differentiation potential. Clinical use requires large cell numbers; which can, theoretically, be generated by ex vivo expansion of pla more

Market studies regenerative medicine

• Global Tissue Engineering and Regeneration Market 2011-2015

  TechNavio’s analysts forecast the Global Tissue Engineering and Regeneration market to grow at a CAGR of 8.5 percent over the period 2011–2015. One of the key factors contributing to this market growth is increased applications in the Skin Integumentary Clinical segment. The Global Tissue Engineerin more

• Stem Cell Technologies: World Market Outlook 2011-2021

  How will the stem cells market develop this decade? Our new report shows you that emerging industry and market's revenue potential from 2011 to 2021. This report covers stem cells in therapeutic applications: technologies, products and services. You will assess events, opportunities and activities more

• Future Directions in Regenerative Medicine

  Big Pharma has begun investing in regenerative medicine: Genzyme in 2008, Pfizer and Novartis in 2009, and Cephalon in 2010. In 3-5 years, investment will reach a “tipping point”, after which no medical industry players will want to be left behind. This report covers the development of therapies to more

Websites regenerative medicine